Trials / Completed
CompletedNCT05613088
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 106 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MORAb-202 | Specified dose on specified days |
| DRUG | Paclitaxel | Specified dose on specified days |
| DRUG | Pegylated Liposomal Doxorubicin (PLD) | Specified dose on specified days |
| DRUG | Topotecan | Specified dose on specified days |
Timeline
- Start date
- 2023-02-01
- Primary completion
- 2024-06-17
- Completion
- 2025-09-11
- First posted
- 2022-11-14
- Last updated
- 2025-10-20
- Results posted
- 2025-07-03
Locations
50 sites across 9 countries: United States, Australia, Belgium, Chile, Israel, Italy, Japan, South Korea, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05613088. Inclusion in this directory is not an endorsement.